On March 6, 2024, the U.S. Securities and Exchange Commission approved a rule to require some companies to report some of their carbon emissions (Scope 1 and 2, but not Scope 3)1. While some feel this rule doesn’t go far enough, it certainly demonstrates the need to better understand our respective carbon footprints and develop…
Why a smart approach to AI-driven drug discovery prioritizes sustainability
The fact that the biopharmaceutical industry has a large carbon footprint is well established. A 2022 study from My Green Lab confirmed that biotech and pharma are still among the globe’s top polluters. The research highlights that a mere 4% of the largest publicly-traded biotech and pharmaceutical firms have climate commitments in line with the…